RevolutionLogo.png
Revolution Medicines Announces Publication of Scientific Paper Describing Anti-Tumor Immunity Induced by SHP2 Inhibitor in Preclinical Cancer Models
April 29, 2020 08:05 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., April 29, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier...
RevolutionLogo.png
Revolution Medicines Announces Issuance of U.S. Patent Covering Compositions of Matter for its Clinical-Stage SHP2 Inhibitor Program
March 18, 2020 07:30 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., March 18, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier...
RevolutionLogo.png
New Clinical Trial Exploring Revolution Medicines’ Investigational SHP2 Inhibitor RMC-4630 in Combination with an ERK Inhibitor Announced by Netherlands Cancer Institute
March 09, 2020 07:30 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., March 09, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier...
RevolutionLogo.png
Revolution Medicines Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
February 18, 2020 16:01 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit elusive...
Toronto Innovation Acceleration Partners (TIAP) adds novel KRAS oncology project to its LAB150 portfolio
December 12, 2019 07:00 ET | Toronto Innovation Acceleration Partners
Toronto, ON, Dec. 12, 2019 (GLOBE NEWSWIRE) -- The low survival rates of three of the four most lethal cancers in North America - pancreatic, colorectal and lung - are associated with KRAS...
effector.jpg
eFFECTOR Therapeutics Initiates Phase 1/2 Safety and Efficacy Study of Zotatifin (eFT226) in Patients with Advanced Solid Tumor Malignancies
November 05, 2019 08:00 ET | eFFECTOR Therapeutics
SAN DIEGO, Nov. 05, 2019 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced the...
PRPO logo.png
Precipio Launches ICE COLD-PCR™ Liquid Biopsy Kit for Pancreatic Cancer
May 17, 2018 07:38 ET | Precipio, Inc.
Ultra-sensitive enrichment kit enables development of low cost detection tests, allowing optimized patient treatment NEW HAVEN, Conn., May 17, 2018 (GLOBE NEWSWIRE) -- Specialty diagnostics company...